Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A new oncolytic virus therapy is showing impressive results for bladder cancer. The phase 3 PIVOT-006 trial found that cretostimogene grenadenorepvec reduced the risk of recurrence or death by 68% compared to surveillance alone in patients with intermediate-risk and high-grade Ta non-muscle-invasive bladder cancer (NMIBC). Notably, no grade 3 or higher treatment-related side effects were reported, signaling a strong safety profile.
A new oncolytic virus therapy is turning heads in bladder cancer treatment. The phase 3 PIVOT-006 trial showed that adjuvant intravesical cretostimogene grenadenorepvec — an engineered oncolytic adenovirus — significantly improved recurrence-free survival (RFS) compared to surveillance alone in patients with intermediate-risk and high-grade Ta non-muscle-invasive bladder cancer (NMIBC) after complete tumor resection.
Developed by CG Oncology, the therapy works via two mechanisms: selectively replicating inside and destroying tumor cells, while also activating an antitumor immune response. The trial enrolled 367 patients who were randomized 1:1 to receive the drug or undergo surveillance following transurethral resection of bladder tumor (TURBT). CG Oncology plans to file a biologics license application (BLA) for this indication with the FDA in 2027.
By the Numbers:
Why it matters: For NMIBC patients, recurrence means repeated invasive procedures and ongoing disease burden. A therapy that dramatically cuts recurrence risk — with a clean safety profile — could meaningfully change clinical practice and improve quality of life for a large population of bladder cancer patients.